Cardinal Health (CAH) has shown consistency in their financial performance, reaffirming their Fiscal 2024 non-GAAP EPS Guidance with an Earnings beat reported and raising Fiscal 2024 Outlook. CAH's stock has experienced moments of both ups and downs, with a 52-week high reached but also a dip following a terminating contract with OptumRx. The company's strategic moves like acquiring Specialty Networks and its PPS Analytics platform and announcing a new business structure and segments hint at the innovativeness. CAH has been reported as a top-value and momentum stock long-term, thanks to solid business growth and huge medical supply market penetration. However, concerns are raised about the potential risk associated with its growth. Regarding their ESG efforts, the company has approved science-based climate targets and expanded focus across the supply chain. Nevertheless, the CEO's selling off shares could cause skepticism among investors.
Cardinal Health CAH News Analytics from Tue, 15 Aug 2023 07:00:00 GMT to Thu, 09 May 2024 12:51:00 GMT -
Rating 6
- Innovation 2
- Information 8
- Rumor 4
